Roeland Nusse
Co-Founder & Member of Scientific Advisory BoardDr. Roeland Nusse, Ph.D., also known as Roel, serves as Member of International Scientific Advisory Board at Nederlands Kanker Instituut. Dr. Nusse serves as Co-Founder and Member of Scientific Advisory Board at Surrozen, Inc. He co-founded Biosplice Therapeutics, Inc. (formerly known as Samumed, LLC) in 2007 and serves as its Advisor. Dr. Nusse has been an Investigator of Howard Hughes Medical Institute since 1990. He has been the Chairman of the Department of Developmental Biology at Stanford University since 2007. He served as Chairman of the Department of Developmental Biology of Stanford University from 1999 to 2003. Dr. Nusse served at the Netherlands Cancer Institute in Amsterdam as a Staff Scientist and ultimately Head of the Department of Molecular Biology. He was a Director at Bio-Techne Corp. since May 28, 2010 until October 29, 2025 and served as its Member of Scientific Advisory Board. He serves as a Member of Scientific and Clinical Advisory Board of OncoMed Pharmaceuticals Inc. He served as a Member of the Scientific Advisory Board of Curis, Inc. He served as a Member of Scientific Advisory Board of Cellerant Therapeutics, Inc. Dr. Nusse served as a Member of European Molecular Biology Organization since 1988. His scientific research and academic background provide valuable strategic insight, including insight into Bio-Techne Corporation’s customers and markets. He was elected to the prestigious United States National Academy of Sciences in April 2010. He was a Member of the Royal Dutch Academy of Science since 1997 and the American Academy of Arts and Sciences since 2001. He serves as a Professor of Developmental Biology, Howard Hughes Medical Institute Stanford University Medical School. He joined Stanford in 1990 as Associate Professor of Developmental Biology and became Full Professor in 1994. Dr. Nusse was awarded the Breakthrough Prize in Life Sciences in 2016. During his career, Dr. Nusse has made several of the most important discoveries regarding Wnt signaling. His studies involve the activity of proteins that determine cell fate during embryogenesis. His research is funded by the Howard Hughes Medical Institute, 2 RO1 grants from the NIH and support from the Cystic Fibrosis Foundation and the JDRF. He is recognized as a key player in various cancers, including human colon cancer. He has received several awards for his work. He holds a Ph.D. and BS Degree in Biology from University of Amsterdam in 1975, Doctorate in Molecular Biology from the Netherlands Cancer Institute in 1980. Dr. Nusse did his Postdoctoral fellowship at the University of California, San Francisco from 1981 to 1982.
Positions
- Company NameSurrozen, Inc.Stock CodeSRZNPositionCo-Founder & Member of Scientific Advisory BoardColleagues
- CCCraig C. ParkerCEO, President & Director
- DJDavid J. WoodhouseIndependent Chairman of the Board
- CWCharles WilliamsCOO & Corporate Secretary
- YLYang LiExecutive Vice President of Research
- KCK. Christopher GarciaCo-Founder & Member of Scientific Advisory Board
- CKCalvin KuoCo-Founder & Member of Scientific Advisor
